Literature DB >> 1657825

Different mechanisms of protection by monoclonal and polyclonal antibodies during the course of herpes simplex virus infection.

A M Eis-Hübinger1, K Mohr, K E Schneweis.   

Abstract

Young adult C57BL mice intravaginally inoculated with herpes simplex virus type 1 and passively immunized with a monoclonal antibody directed against herpes simplex virus type 1 glycoprotein gB were shown to be more effectively protected against infection as compared with mice treated with polyclonal immune serum. In contrast to polyclonal antiserum, the monoclonal antibody markedly restricted viral multiplication in the infected mucous membranes. Consequently, skin lesions were completely prevented, and the extent of ganglionic infection was significantly reduced. The mechanism by which a monoclonal antibody, specific to glycoprotein gC, effected protection also differed from that of the hyperimmune serum, since premature latency was not induced. The data provide strong evidence that the mechanisms of protection mediated by antibodies depend on their epitope specificity. The inhibition of active antibody response after passive immunization was inducible by polyclonal antibody only, not by monoclonal antibodies.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1657825     DOI: 10.1159/000150219

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  7 in total

1.  Characterisation of the epitope for a herpes simplex virus glycoprotein B-specific monoclonal antibody with high protective capacity.

Authors:  Martin P Däumer; Beate Schneider; Doris M Giesen; Sheriff Aziz; Rolf Kaiser; Bernd Kupfer; Karl E Schneweis; Jens Schneider-Mergener; Ulrich Reineke; Bertfried Matz; Anna M Eis-Hübinger
Journal:  Med Microbiol Immunol       Date:  2010-10-08       Impact factor: 3.402

2.  Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virus.

Authors:  Adalbert Krawczyk; Jürgen Krauss; Anna M Eis-Hübinger; Martin P Däumer; Robert Schwarzenbacher; Ulf Dittmer; Karl E Schneweis; Dirk Jäger; Michael Roggendorf; Michaela A E Arndt
Journal:  J Virol       Date:  2010-12-01       Impact factor: 5.103

3.  The role of the immune system in establishment of herpes simplex virus latency--studies using CD4+ T-cell depleted mice.

Authors:  D S Schmidt; A M Eis-Hübinger; K E Schneweis
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

Review 4.  Glycoprotein targeted therapeutics: a new era of anti-herpes simplex virus-1 therapeutics.

Authors:  Thessicar E Antoine; Paul J Park; Deepak Shukla
Journal:  Rev Med Virol       Date:  2013-02-26       Impact factor: 6.989

5.  Directed selection of recombinant human monoclonal antibodies to herpes simplex virus glycoproteins from phage display libraries.

Authors:  P P Sanna; R A Williamson; A De Logu; F E Bloom; D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-03       Impact factor: 11.205

6.  Prevention of herpes simplex virus induced stromal keratitis by a glycoprotein B-specific monoclonal antibody.

Authors:  Adalbert Krawczyk; Miriam Dirks; Maren Kasper; Anna Buch; Ulf Dittmer; Bernd Giebel; Lena Wildschütz; Martin Busch; Andre Goergens; Karl E Schneweis; Anna M Eis-Hübinger; Beate Sodeik; Arnd Heiligenhaus; Michael Roggendorf; Dirk Bauer
Journal:  PLoS One       Date:  2015-01-14       Impact factor: 3.240

Review 7.  Monoclonal antibody therapy of herpes simplex virus: An opportunity to decrease congenital and perinatal infections.

Authors:  Iara M Backes; David A Leib; Margaret E Ackerman
Journal:  Front Immunol       Date:  2022-08-09       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.